Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.

Published in: Molecular imaging and biology (2020)

Our studies establish DARA-IRDye800 as a promising contrast agent for preclinical evaluation of CD38 expression and for further investigating myeloma engraftment and kinetics in relation to anti-CD38 therapies.

Keyphrases

multiple myeloma
high resolution
nk cells
poor prognosis
magnetic resonance
cell therapy
drug delivery
cancer therapy
mesenchymal stem cells
case control
fluorescence imaging